Why Diabetes Is Leading the Digital Therapeutics Market, and Where It Goes Next

Healthcare is moving toward care that is software-driven, measurable and delivered outside the clinic. Digital therapeutics (DTx) sit at the center of that shift. These are clinically evaluated software interventions designed to prevent, manage or treat medical conditions, and they are fast becoming part of mainstream treatment pathways.

According to Grand View Research, the global digital therapeutics market was valued at USD 9.5 billion in 2025. It is projected to grow from USD 12.0 billion in 2026 to USD 75.2 billion by 2033, a CAGR of 30.0%. North America led in 2025 with a 39.8% revenue share.

Key Market Segments & Applications

By application

Diabetes is the largest application segment, with a 30.1% revenue share in 2025, and it is also expected to grow fastest, at a 31.6% CAGR. The disease burden is large: the CDC estimates 40.1 million people in the U.S. had diagnosed or undiagnosed diabetes in 2023. Pairing DTx with continuous glucose monitoring, wearables and AI-enabled analytics is extending these tools from basic tracking to continuous, data-driven care.

Obesity is the second-largest segment, driven by demand for scalable weight-management support such as coaching, nutrition guidance and activity tracking. Cardiovascular disease, respiratory diseases, smoking cessation and CNS disorders (including depression, anxiety, ADHD and insomnia) are also expanding, with newer products reaching neurology and psychiatry, such as migraine and schizophrenia.

By end use

• Patients held the largest share in 2025 at 35.0% and are expected to grow fastest. People increasingly want personalized, remotely accessible programs for chronic disease management.
• Employers are projected to grow at a 30.8% CAGR as companies add clinically supported digital tools to benefits programs to manage healthcare costs and support preventive care.
• Providers and payers are integrating DTx into clinical workflows and value-based care models, with real-world outcomes increasingly informing coverage decisions.

By region

North America is the largest market, and the U.S. accounts for 82.6% of the regional total. Asia Pacific is the fastest-growing region, at a 32.1% CAGR, fueled by healthcare digitization, smartphone penetration, aging populations and government investment in digital health.

Want the full picture? Download Free Sample Get market data points, trend analysis and forecasts from the full report.

Growth drivers

• Rising chronic disease burden. CDC data show 76.4% of U.S. adults reported at least one chronic condition in 2023, and 51.4% reported two or more. Conditions like these need continuous monitoring and behavioral support, which software can deliver at scale.
• Smartphone and internet penetration. Wider access to connected devices lets patients receive therapy and share data with clinicians outside traditional settings.
• Supportive regulation and reimbursement. CMS introduced new remote therapeutic monitoring codes in January 2026, covering therapy adherence, therapy response and digital therapeutic interventions. Germany's DiGA framework offers an established route to statutory reimbursement.
• AI and connected-device integration. AI can turn wearable and patient-reported data into adaptive, personalized interventions. In July 2026, the FDA selected Dexcom as the first participant in its TEMPO pilot, which supports real-world evidence generation for digital health devices in chronic disease management.
• Investment momentum. Funding is flowing toward companies with clinical evidence, healthcare partnerships and clear commercialization pathways.

Challenges

• Regulatory and reimbursement complexity. Developers must show clinical efficacy, safety, usability and data security across different regulatory regimes. Reimbursement remains inconsistent across therapeutic areas and countries, and no universal coverage exists for DTx.
• Costly, slow evidence generation. Building the clinical proof that payers and physicians expect lengthens development timelines and raises costs.
• Adoption hurdles. Physician acceptance, patient engagement and sustainable business models remain decisive for commercial success.

Speak to Analyst Talk to the report's research team about your specific questions.

Competitive Landscape & Market Leaders

The market brings together specialized DTx developers, pharmaceutical companies and digital health technology providers. Key companies profiled in the report include 2Morrow, Big Health, Canary Health, DarioHealth, GAIA AG, Hygieia, Noom, Omada Health, ResMed, Teladoc Health, Virtual Therapeutics and Welldoc.

Two broad groups are emerging:

• Established players such as Omada Health, Teladoc Health and DarioHealth lean on brand recognition, large patient populations, payer and employer relationships, and scalable platforms across diabetes, cardiovascular health, obesity and wellness.
• Specialized players such as Big Health and GAIA AG focus on niche areas like mental health and disease-specific interventions. They innovate quickly but face tighter resources and reimbursement dependence.

Recent deals show where the industry is heading:

• July 2026: XRHealth acquired Swing Therapeutics, adding FDA-authorized DTx for fibromyalgia and chronic pain.
• April 2026: Boehringer Ingelheim committed USD 50 million to Click Therapeutics to support commercialization of CT-155, an investigational schizophrenia DTx.
• January 2026: Click Therapeutics and Ultrahuman partnered on a biomarker-driven migraine management tool.

The pattern is convergence: pharma expertise, wearables and AI are being combined with clinically validated software.

The Road Ahead

The next phase of growth will depend on stronger clinical evidence, smoother integration into routine care and reimbursement models that reward measurable outcomes. Companies that can show clinical and economic value, and fit into payer and provider workflows, are best placed to lead a market projected to be worth USD 75.2 billion by 2033.

Explore our dedicated business services:

Prism AI: Market Intelligence with Cited Research- Ask questions in plain language and get insights drawn from Grand View Research's entire research library, with sources cited. Create your free account today.

U.S. Healthcare Facility Mapping & Intelligence Platform: Get facility-level intelligence to guide smarter decisions. Sign up Today